In an adult with vertebral osteomyelitis caused by a single identified organism with susceptibility testing, what single‑agent antibiotic regimens are recommended?

Single-Agent Antibiotic Options for Vertebral Osteomyelitis

For vertebral osteomyelitis with identified organisms and susceptibility data, single-agent parenteral therapy is recommended for most common pathogens, with specific first-line choices based on the causative organism: nafcillin/oxacillin or cefazolin for methicillin-susceptible staphylococci, vancomycin for methicillin-resistant staphylococci, cefepime or meropenem for Pseudomonas, and fluoroquinolones for susceptible gram-negative organisms. 1

Organism-Specific Single-Agent Regimens

Staphylococci (Oxacillin-Susceptible)

First-line single agents:

• Nafcillin or oxacillin 1.5-2 g IV every 4-6 hours (preferred)
• Cefazolin 1-2 g IV every 8 hours (excellent alternative)
• Ceftriaxone 2 g IV once daily (convenient dosing)

All regimens should be administered for 6 weeks duration 1. These beta-lactams provide superior outcomes for methicillin-susceptible S. aureus (MSSA), the most common cause of vertebral osteomyelitis.

Staphylococci (Oxacillin-Resistant)

First-line single agent:

• Vancomycin 15-20 mg/kg IV every 12 hours with loading dose and serum level monitoring

Alternative single agents:

• Daptomycin 6-8 mg/kg IV once daily (particularly effective based on recent data) 2
• Linezolid 600 mg PO/IV every 12 hours

Duration: 6 weeks 1. Daptomycin-containing regimens showed strong association with clinical cure in a 2020 prospective study, with significantly better outcomes than other regimens 2.

Enterococcus Species (Penicillin-Susceptible)

Single-agent options:

• Penicillin G 20-24 million units IV daily (continuously or in 6 divided doses)
• Ampicillin 12 g IV daily (continuously or in 6 divided doses)

Important caveat: While single-agent therapy is acceptable for vertebral osteomyelitis, aminoglycoside addition is mandatory for 4-6 weeks if concurrent endocarditis exists 1.

Pseudomonas aeruginosa

Single-agent options:

• Cefepime 2 g IV every 8-12 hours
• Meropenem 1 g IV every 8 hours
• Ciprofloxacin 750 mg PO every 12 hours or 400 mg IV every 8 hours

Duration: 6 weeks 1. A 2013 study demonstrated that oral ciprofloxacin over 6-8 weeks was the most effective treatment for gram-negative vertebral osteomyelitis, with 5 of 8 successfully treated patients receiving ciprofloxacin 3.

Enterobacteriaceae

Single-agent options:

• Cefepime 2 g IV every 12 hours
• Ertapenem 1 g IV once daily
• Ciprofloxacin 500-750 mg PO every 12 hours or 400 mg IV every 12 hours

Duration: 6 weeks 1. Fluoroquinolones offer excellent oral bioavailability and bone penetration for susceptible gram-negative organisms.

Beta-Hemolytic Streptococci

Single-agent options:

• Penicillin G 20-24 million units IV daily (continuously or in 6 divided doses)
• Ceftriaxone 2 g IV once daily

Duration: 6 weeks 1.

Propionibacterium acnes (Cutibacterium)

Single-agent option:

• Penicillin G 20 million units IV daily
• Ampicillin IV followed by oral amoxicillin (based on 2022 case report of successful treatment) 4

Oral Single-Agent Options for Transition or Initial Therapy

The 2015 IDSA guidelines support early transition to oral therapy when clinically appropriate 1. Oral agents with excellent bioavailability suitable for single-agent use include:

For Gram-Negative Organisms:

• Ciprofloxacin 500-750 mg PO twice daily (for Pseudomonas, Enterobacteriaceae, Salmonella)
• Levofloxacin 500-750 mg PO once daily (for Enterobacteriaceae)
• Moxifloxacin 400 mg PO once daily (for Enterobacteriaceae)

Critical caveat: Fluoroquinolones are NOT recommended as monotherapy for staphylococcal vertebral osteomyelitis 1.

For Oxacillin-Resistant Staphylococci:

• Linezolid 600 mg PO twice daily (when first-line agents cannot be used)

For Anaerobes:

• Metronidazole 500 mg PO 3-4 times daily (for Bacteroides species)

For Brucellar Osteomyelitis:

While typically combination therapy, doxycycline 100 mg PO twice daily is a core component, though guidelines recommend combining with rifampin or streptomycin 1.

Key Clinical Considerations

Duration of therapy: All regimens require minimum 6 weeks total duration of antimicrobial therapy 1. Early switch to oral therapy (after approximately 12 days IV) may be safe provided C-reactive protein has decreased and significant abscesses have been drained 1.

Common pitfall: Do not use fluoroquinolones as single agents for staphylococcal infections—they have unacceptably high failure rates despite in vitro susceptibility 1.

Monitoring: Failure to improve CRP levels during follow-up is an independent risk factor for treatment failure 5. Track inflammatory markers, not just clinical symptoms.

Surgical indications: Single-agent antibiotic therapy may fail if there is inadequate drainage of infection, involvement of >2 vertebrae, or presence of significant epidural abscess 2. These patients require surgical intervention regardless of antibiotic choice.

Beta-lactam oral switch: A 2019 Korean study suggests that switching to oral beta-lactams may be safe in selected MSSA vertebral osteomyelitis patients, though this remains controversial and is not formally endorsed in guidelines 5.